Vir Biotechnology, Inc. (VIR)
After hours:
Chart Events
Performance Outlook
| Previous Close | 28.84 |
| Open | 25.00 |
| Bid | 27.50 x 1800 |
| Ask | 30.67 x 1000 |
| Day's Range | 24.52 - 31.15 |
| 52 Week Range | 18.21 - 58.00 |
| Volume | |
| Avg. Volume | 942,782 |
| Market Cap | 4.011B |
| Beta (5Y Monthly) | -0.45 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.80 |
| Earnings Date | Feb 23, 2022 - Feb 28, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 55.50 |
- Benzinga
Vir Biotech Shuns FDA Submission Plans For GSK-Partnered COVID-19 Treatment
In its Q2 earnings release, Vir Biotechnology Inc (NASDAQ: VIR) and its partner GSK plc (NYSE: GSK) said that they do not plan to file a marketing application for sotrovimab for COVID-19 at this time. The company also said it does not intend to pursue the US-based Phase 3 COMET-STAR prophylaxis trial, citing evolving COVID-19 landscape and FDA discussions. Discussions with the FDA remain ongoing regarding the appropriate path forward for sotrovimab in the U.S. Related: Why Did FDA Pull Authoriza
- Zacks
Vir Biotechnology, Inc. (VIR) Reports Q2 Loss, Misses Revenue Estimates
Vir Biotechnology, Inc. (VIR) delivered earnings and revenue surprises of -241.18% and 129.79%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2022 Financial Results
– More than $2.6 billion in cash, cash equivalents, investments and profit-share payments to be received from GSK expected to fund the company’s ongoing operations and liabilities for up to five years – – Company provides update on COVID-19 development program and outlines multiple anticipated value drivers from its robust pipeline – SAN FRANCISCO, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the seco
